Abstract
Patients using deep brain stimulation (DBS) with adjunctive oral therapy may require additional therapies like levodopa-carbidopa intestinal gel (LCIG), known as CLES in the United States. We examine use of oral/transdermal anti-parkinsonian medications in advanced Parkinson's disease (APD) patients with history of or current treatment with DBS, receiving LCIG.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
